Yalcin, S. Et Al. 2012. Phase II study of adjuvant imatinib mesylate (IM) in patients after resection of primary gastrointestinal stromal tumor (GIST): Efficacy and safety at one year.. 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) , (Illinois, United States Of America).

Yalcin, S., Buyukberber, S., Yilmaz, U., Lee, P., Srimuninnimit, V., Lin, P., ... Elserafy, M. M.(2012). Phase II study of adjuvant imatinib mesylate (IM) in patients after resection of primary gastrointestinal stromal tumor (GIST): Efficacy and safety at one year. . 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America

Yalcin, ŞUAYİB Et Al. "Phase II study of adjuvant imatinib mesylate (IM) in patients after resection of primary gastrointestinal stromal tumor (GIST): Efficacy and safety at one year.," 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 2012

Yalcin, ŞUAYİB Et Al. "Phase II study of adjuvant imatinib mesylate (IM) in patients after resection of primary gastrointestinal stromal tumor (GIST): Efficacy and safety at one year.." 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) , Illinois, United States Of America, 2012

Yalcin, S. Et Al. (2012) . "Phase II study of adjuvant imatinib mesylate (IM) in patients after resection of primary gastrointestinal stromal tumor (GIST): Efficacy and safety at one year.." 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) , Illinois, United States Of America.

@conferencepaper{conferencepaper, author={ŞUAYİB YALÇIN Et Al. }, title={Phase II study of adjuvant imatinib mesylate (IM) in patients after resection of primary gastrointestinal stromal tumor (GIST): Efficacy and safety at one year.}, congress name={48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)}, city={Illinois}, country={United States Of America}, year={2012}}